首页> 美国卫生研究院文献>Journal of Clinical Oncology >PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

【2h】

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

机译：PointBreak：培美曲塞加卡铂和贝伐单抗继之维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐珠单抗继之贝伐单抗维持治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposePointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC).

机译：PurposePointBreak（一项针对非鳞状非小细胞肺癌患者的培美曲塞，卡铂和贝伐单抗的研究）比较了培美曲塞（Pem）加卡铂（C）加贝伐单抗（Bev），培美曲塞加贝伐珠单抗（PemCBev）对于晚期非鳞状非小细胞肺癌（NSCLC）患者，紫杉醇（Pac）加卡铂（C）加贝伐单抗（Bev），然后贝伐单抗（PacCBev）。

著录项

期刊名称 Journal of Clinical Oncology
作者
Jyoti D. Patel; Mark A. Socinski; Edward B. Garon; Craig H. Reynolds; David R. Spigel; Mark R. Olsen; Robert C. Hermann; Robert M. Jotte; Thaddeus Beck; Donald A. Richards; Susan C. Guba; Jingyi Liu; Bente Frimodt-Moller; William J. John; Coleman K. Obasaju; Eduardo J. Pennella; Philip Bonomi; Ramaswamy Govindan;
展开▼
作者单位

展开▼
年(卷),期 -1(31),34
年度 -1
页码 4349–4357
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
入库时间 2022-08-21 10:53:19

相似文献

外文文献
中文文献
专利

1. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. [J] . Patel JD, Bonomi P, Socinski MA, Clinical lung cancer . 2009,第4期

机译：突破性研究的治疗原理和研究设计：培美曲塞/卡铂/贝伐单抗的随机，开放标签III期研究，然后进行培美曲塞/贝伐单抗与紫杉醇/卡铂/贝伐单抗的维持治疗，对IIIB或IV期非鳞状非IV期患者进行贝伐珠单抗治疗-小细胞肺癌。
2. Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [J] . Spigel David R., Patel Jyoti D., Reynolds Craig H., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第2期

机译：生活质量分析来自于培美曲塞-卡铂-贝伐单抗，维持培美曲塞-贝伐单抗与紫杉醇-卡铂-贝伐单抗再继之维持贝伐单抗的培美曲塞-卡铂-贝伐单抗的随机，开放标签，III期PointBreak研究，分析了IIIB或IV期非鳞状非-S患者细胞肺癌
3. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [J] . Jyoti D. Patel, Mark A. Socinski, Edward B. Garon, Journal of Clinical Oncology . 2013,第34期

机译：PointBreak：培美曲塞加卡铂和贝伐单抗继之以维持治疗的随机III期研究ⅢB或IV期非鳞状非小细胞肺癌患者培美曲塞和贝伐单抗与紫杉醇加卡铂和贝伐单抗继之以贝伐单抗维持治疗
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. PRONOUNCE: Randomized Open-Label Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer [O] . Ralph G. Zinner, Coleman K. Obasaju, David R. Spigel, -1

机译：代名词：晚期非鳞状非小细胞肺癌患者一线培美曲塞+卡铂联合维持培美曲塞与紫杉醇+卡铂+贝伐单抗+贝伐珠单抗一线治疗的随机开放标签III期研究
7. Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer [O] . Spigel David R., Patel Jyoti D., Reynolds Craig H., 2015

机译：生活质量分析来自于培美曲塞-卡铂-贝伐单抗，维持培美曲塞-贝伐单抗与紫杉醇-卡铂-贝伐单抗再继之维持贝伐单抗的培美曲塞-卡铂-贝伐单抗的随机，开放标签，III期PointBreak研究，分析IIIB或IV期非鳞状非-S期患者细胞肺癌

摘要

著录项

相似文献

相关主题

期刊订阅